Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today that J.P.
Morgan Securities LLC and Goldman, Sachs & Co., the lead book-running
managers in the Company's recent public sale of 5,060,000 shares of
common stock, are releasing a lock-up restriction with respect to 7,563
shares of the Company's common stock held by Keith Leonard, President
and Chief Executive Officer of the Company, to allow Mr. Leonard to make
a charitable donation to a not-for-profit entity. The release will tak
effect on December 21, and the shares will be transferred to the
not-for-profit entity and may be sold by that entity on or after such
This press release is not an offer for sale of the securities in the
United States or in any other jurisdiction where such offer is
prohibited, and such securities may not be offered or sold in the United
States absent registration or an exemption from registration under the
United States Securities Act of 1933, as amended.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of
novel prescription products for the aesthetic medicine market. KYTHERA's
product candidate, ATX-101, is a potential first-in-class, injectable
treatment currently in Phase III clinical development for the reduction
of submental fat, which commonly presents as an undesirable "double
chin." KYTHERA also maintains an active research interest in hair and
fat biology, pigmentation modulation and facial contouring. Find more
information at http://www.kytherabiopharma.com.
[ Back To NFVZone's Homepage ]